Today: 30 April 2026
American Express stock (AXP) ends flat as Trump’s 10% credit-card cap keeps policy risk in play
15 January 2026
2 mins read

American Express stock (AXP) ends flat as Trump’s 10% credit-card cap keeps policy risk in play

New York, Jan 14, 2026, 21:06 EST — Market closed.

American Express shares ended Wednesday slightly higher, gaining 0.07% to close at $358.26. The stock steadied after a volatile start to the week for credit card companies. U.S. bank stocks remained under pressure as investors weighed President Donald Trump’s efforts to limit credit card interest rates.

The policy debate is crucial since American Express and other card issuers depend heavily on interest income and fees. A strict cap could squeeze their margins or alter how they underwrite loans. U.S. House Speaker Mike Johnson acknowledged Congress should consider the proposal but cautioned about “negative secondary effects” if lenders reduce credit access. Reuters

Investors are keeping an eye on the Credit Card Competition Act, which Senators Roger Marshall and Dick Durbin reintroduced this week. According to a statement from Marshall’s office, the bill would force large banks to support at least two unaffiliated card networks for credit-card transactions, including one beyond Visa and Mastercard. This targets the current “swipe fee” system, or interchange fees, that merchants pay on card purchases. Senator Roger Marshall

The sell-off has hit broadly. Visa shares dropped roughly 7% since Monday, American Express fell about 5%, and Mastercard slid close to 5%, Investopedia reports. William Blair analysts see the dip as a buying opportunity, urging long-term investors to “accumulate” these stocks despite current uncertainty. Citigroup’s team also noted that previous sell-offs sparked by worries over their business models have often rewarded those who stepped in. Investopedia

Markets are pricing in the headlines as a genuine near-term drag, despite widespread skepticism on Wall Street about the chances of swift approval. “Financials are getting hit by Trump’s credit-card proposal,” said Tim Ghriskey, senior portfolio strategist at Ingalls & Snyder, on Tuesday. He added that turning the proposal into reality would be “extremely difficult.” Reuters

A smaller competitor threw a curveball Wednesday. New York-based fintech Bilt announced a 10% introductory annual percentage rate (APR) for the first year on new cards. CEO Ankur Jain stated, “If (a credit card rate cap) is going to happen, we’d rather be at the forefront.” This move might ramp up political pressure on larger issuers like American Express. AP News

But the downside is clear. Citi CFO Mark Mason argued a 10% cap would block credit access for those who need it most and cause a “deleterious impact” on the economy. CEO Jane Fraser added that the damage to banks would be “dwarfed” by the blow to consumer spending if credit tightens. Business Insider

Thursday’s session will hinge on Washington. Traders will watch closely for any sign the administration can push a viable legislative plan, or if the proposal will remain just a headline that fades away. The longer uncertainty drags on, the more it could drag down valuations throughout the card complex.

American Express is set to release its fourth-quarter and full-year 2025 results on Jan. 30. The earnings materials will drop around 7 a.m. ET, followed by an 8:30 a.m. conference call. Investors will get a fresh update on spending patterns and credit costs, even as the policy debate continues in the background.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Oklo stock slips after insider sales filing; CEO flags labor crunch for nuclear buildout
Previous Story

Oklo stock slips after insider sales filing; CEO flags labor crunch for nuclear buildout

OpenAI’s $10B Cerebras compute deal: 750MW push to make ChatGPT faster
Next Story

OpenAI’s $10B Cerebras compute deal: 750MW push to make ChatGPT faster

Go toTop